Search
for
Sort by
Research
90-120 / 1000+ results
research Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research Kudos
The document cannot be understood or processed.
research Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes
A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
research Alopecia associated with atorvastatin
Atorvastatin may cause hair loss in some people.
research Fluxactive Complete (#1 PREMIUM PROSTATE SUPPORT FORMULA) Managing Prostate Wellness And Bladder Functions!
research Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
research Meetings and Studies: Review of the 19th Annual Orlando Live Surgery Workshop April 17-20, 2013 • Orlando, Florida
The document's content cannot be summarized because it is not accessible or understandable.
research MAGİSTRAL AVTOMOBİL YOLLARI. TARIXİ, TORPAQ SAHƏSİ, MÜASİR VƏZİYYƏTİ, PROBLEMLƏRİ
The document's conclusion cannot be provided because the content is not in a readable format.
research 10.1063/5.0132123.1
research Circumscribed Alopecia Areata Incognita and Response to Tofacitinib
Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
research Type A insulin resistance syndrome due to a novel heterozygous c.3486_3503del (p. Arg1163_Ala1168del) INSR gene mutation in an adolescent girl and her mother
A new gene mutation causes insulin resistance in a girl and her mother.
research AI03 Steps towards safely deploying the world’s first autonomous artificial intelligence as a medical device for skin cancer into a National Health Service teledermatology pathway
An AI device for skin cancer was successfully integrated into the NHS, improving diagnosis accuracy and service capacity.
research Live Workshop 1996
The document cannot be understood or processed.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
research Topical tofacitinib in treatment of alopecia areata
Topical tofacitinib shows promise as a future treatment for alopecia areata.
research Resistant alopecia areata treated with tofacitinib
Tofacitinib can be effective in treating hair loss caused by alopecia areata.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research 16．微生物学研究室
research 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
research Review of the 6th AAHRS Annual Scientific Meeting and 3rd CAHRS Annual Congress May 11-13, 2018 Beijing, China
The document's content couldn't be processed.
research Abstracts Presented at 41st Annual, 9th International Conference of the Islamic Medical Association of North America and First Joint Conference with the Federation of Islamic Medical Associations (FIMA), July 31-August 2, 2008
The document's content cannot be summarized because it is not accessible or understandable.
research A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
research DEEP REINFORCEMENT LEARNING FOR SCALABLE CONTROL OF BOOLEAN MODELS IN THE CONTEXT OF CELLULAR REPROGRAMMING
pbn-STAC effectively finds strategies for cellular reprogramming using deep reinforcement learning.
research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
research Review of the ABCRC Controversies Workshop May 13-14, 2016 • Fortaleza, Brazil
The document's content cannot be summarized because it is not accessible or understandable.